Listen to this article

Tevogen has completed and opened its newly expanded corporate headquarters in Warren, the biotech company announced July 10.

Dr. Ryan Saadi, Tevogen founder and CEO, gifted $500,000 for the build-out and first-year operating costs of the site. As a result, the company and shareholders incurred no expense for the move.

“This contribution is about belief in Tevogen’s mission, in the remarkable people who bring that mission to life, and in the future we are building together,” Saadi said in a June 30 statement announcing the funding. “Our purpose is more than a business plan; it is a shared promise to patients, to one another, and to the society we serve. I am grateful for how far we have come and confident in the road ahead.”

In June, the company announced the lease agreement that more than doubles Tevogen’s footprint.

Completed ahead of schedule, the new facility brings research, regulatory and the expanding Tevogen.AI teams together under one roof, the company announced.

“This personal investment by our CEO underscores the conviction of Tevogen’s leadership in our long-term vision of accessible, affordable cell therapies,” said Kirti Desai, chief financial officer. “We expect it to enable us to scale efficiently while maintaining our commitment to capital discipline.”

The company is also planning a formal ribbon-cutting ceremony for the new site and will invite local officials, employees and community partners.

Tevogen develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers and other disorders, according to its website. In April, the company reaffirmed its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative five-year estimate of between $10 billion and $14 billion.